Prostate specific antigen based prostate cancer screening: accumulating evidence of efficacy but persistent uncertainty

Editorial

Gerald L Andriole. J Urol. 2005 Aug.

. 2005 Aug;174(2):413-4.

doi: 10.1097/01.ju.0000171051.35187.d0.

No abstract available

Comment on

4-year prostate specific antigen progression and diagnosis of prostate cancer in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam.
Schröder FH, Raaijmakers R, Postma R, van der Kwast TH, Roobol MJ. Schröder FH, et al. J Urol. 2005 Aug;174(2):489-94; discussion 493-4. doi: 10.1097/01.ju.0000165568.76908.5c. J Urol. 2005. PMID: 16006878
Screening with prostate specific antigen and metastatic prostate cancer risk: a population based case-control study.
Kopec JA, Goel V, Bunting PS, Neuman J, Sayre EC, Warde P, Levers P, Fleshner N. Kopec JA, et al. J Urol. 2005 Aug;174(2):495-9; discussion 499. doi: 10.1097/01.ju.0000165153.83698.42. J Urol. 2005. PMID: 16006879
Results of compliance with prostate cancer screening guidelines.
Grubb RL, Roehl KA, Antenor JA, Catalona WJ. Grubb RL, et al. J Urol. 2005 Aug;174(2):668-72; discussion 672. doi: 10.1097/01.ju.0000165149.66186.23. J Urol. 2005. PMID: 16006944